Viramune Contraindications



Boehringer Ingelheim


Full Prescribing Info
VIRAMUNE is contraindicated in patients with clinically significant hypersensitivity to the active ingredient or any of the excipients in the product.
VIRAMUNE should not be administered to patients with severe hepatic dysfunction (Child-Pugh C) or pre-treatment ASAT or ALAT >5X Upper Limit of Normality (ULN) until baseline ASAT/ALAT are stabilised (<5X ULN).
VIRAMUNE should not be readministered to patients who have required permanent discontinuation for severe rash, rash accompanied by constitutional symptoms, hypersensitivity reactions, or clinical hepatitis due to nevirapine.
VIRAMUNE should not be readministered in patients who previously had ASAT or ALAT >5X Upper Limit of Normality (ULN) during nevirapine therapy and had recurrence of liver function abnormalities upon readministration of nevirapine, (see Precautions).
In case of rare hereditary conditions that may be incompatible with an excipient of the product (see Precautions) the use of the product is contraindicated.
Herbal preparations containing St John's wort (Hypericum perforatum) must not be used while taking VIRAMUNE due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine (see Interactions).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in